Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing
On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of…
On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of…
On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…
On Dec. 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of…
On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…
On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dec. 10, 2020, ImmunityBio announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates…
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dev. 8, 2020, University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials…
On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
On Dec. 7, 2020, the Serum Institute of India (SII) announced that it had applied to Drugs Controller…
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…
On Dec. 4, 2020, VBI Vaccines and Syneos Health announced a partnership for the commercialization of VBIメs 3-antigen…
On Dec. 3, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended, as interim guidance, that both 1)…
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
On Dec. 2, 2020, the first COVID-19 vaccine for the UK, developed by Pfizer/BioNTech, was given approval for…
On Dec. 2, 2020, Codex DNA announced the release of seven new synthetic SARS-CoV-2 genomes for use in…
On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…
On Dec. 1, 2020, Pfizer and BioNTech announced they had submitted on Nov. 30, 2020, a formal Application…
On Nov. 30, 2020, a City of Hope investigational vaccine produced strong protective immunity against SARS-CoV-2, including neutralizing antibodies…
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored…
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
On Nov. 25, 2020, BioNTech and Shanghai Fosun Pharmaceutica jointly announced that their lead mRNA COVID-19 vaccine candidate…
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
On Nov. 24, 2020, Roche announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental…